Trafficking Signals in P. Falciparum
恶性疟原虫的贩运信号
基本信息
- 批准号:7632270
- 负责人:
- 金额:$ 41.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-08-15 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AntigensAntimalarialsBiochemicalBiochemical GeneticsBioinformaticsBiological AssayBiologyCell FractionationCell membraneCellsChildCommunicable DiseasesCytoplasmDestinationsDrug resistanceEmployee StrikesErythrocyte MembraneErythrocytesEventGene ExpressionGenesHealthHeat shock proteinsHumanImaging TechniquesIn VitroInfectionKnock-outMalariaMammalian CellMediatingMembraneModelingModificationMolecularMolecular ChaperonesMolecular GeneticsOrganellesParasitesPathway interactionsPharmaceutical PreparationsPlasmodium falciparumProtein Export PathwayProteinsReporterResolutionRoleSeverity of illnessSignal TransductionSorting - Cell MovementStructureSurfaceTransfectionVacuoleVariantVirulenceVirulentYeastsdrug developmentlink proteinreceptortooltrafficking
项目摘要
DESCRIPTION (provided by applicant): Malaria is a major infectious disease. Conservative estimates predict 2-300 million people are afflicted and over a million children die from the infection each year. The growing threat of drug resistant forms of malaria has created an urgent requirement for new drugs. Targeting unique features of the parasite not found in host cells provides one approach to new drug development. Plasmodium falciparum causes the most virulent form of human malaria. A striking feature of P. falciparum erythrocytic infection is targeting parasite proteins to the red cell. We have shown that targeting events are mediated by unique host-targeting signals on the proteins. Unlike organelles of yeast and mammalian cells, destinations in the red cell lie beyond the plasma membrane of the parasite. Moreover, the red cell has no endogenous transport structures or machinery. The long term aim of this proposal is to understand and characterize how the erythrocyte membrane is accessed by the intracellular parasite and the identification of erythrocyte chaperones and other erythrocyte targets that interact with critical parasite factors. The studies will contribute to our understanding of basic mechanisms of erythrocyte modification, biology of the parasite as well as open up new targets for anti-malarial therapy, and thereby contribute to human health. Molecular, genetic tools using transfection combined with bioinformatics, high resolution imaging techniques and biochemical subcellular fractionation assays will be used to express secretory constructs as trans genes and evaluate knockouts in infected erythrocytes. The consequence of trans gene expression and knock outs on variant antigen expression on the erythrocyte surface will be evaluated. These studies are important for understanding existing mechanisms of erythrocyte remodeling and malarial virulence.
描述(由申请人提供):疟疾是一种主要的传染病。据保守估计,每年有2- 3亿人受到感染,100多万儿童死于感染。抗药性疟疾的威胁日益严重,迫切需要新的药物。针对宿主细胞中未发现的寄生虫的独特特征提供了一种新药开发的方法。恶性疟原虫是最致命的人类疟疾。恶性疟原虫红细胞感染的一个显著特征是将寄生虫蛋白靶向红细胞。我们已经表明,靶向事件是由蛋白质上独特的宿主靶向信号介导的。与酵母和哺乳动物细胞的细胞器不同,红细胞的目的地位于寄生虫的质膜之外。此外,红细胞没有内源性运输结构或机制。该提案的长期目标是了解和表征红细胞膜如何被细胞内寄生虫访问,并鉴定与关键寄生虫因子相互作用的红细胞伴侣蛋白和其他红细胞靶标。这些研究将有助于我们了解红细胞修饰的基本机制,寄生虫的生物学以及开辟抗疟疾治疗的新靶点,从而为人类健康做出贡献。使用转染与生物信息学、高分辨率成像技术和生化亚细胞分级分离测定相结合的分子遗传工具将用于表达作为转基因的分泌构建体,并评估受感染红细胞中的敲除。将评价转基因表达和敲除对红细胞表面变体抗原表达的影响。这些研究对于了解红细胞重塑和疟疾毒力的现有机制具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KASTURI HALDAR其他文献
KASTURI HALDAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KASTURI HALDAR', 18)}}的其他基金
Malaria Phosphatase Inhibitors Identified as a Potential New Malaria Treatment
疟疾磷酸酶抑制剂被确定为潜在的新疟疾治疗方法
- 批准号:
8476279 - 财政年份:2012
- 资助金额:
$ 41.81万 - 项目类别:
Malaria Phosphatase Inhibitors Identified as a Potential New Malaria Treatment
疟疾磷酸酶抑制剂被确定为潜在的新疟疾治疗方法
- 批准号:
8262565 - 财政年份:2012
- 资助金额:
$ 41.81万 - 项目类别:
MECHANISMS OF ERYTHROCYTIC INFECTIONS AND ANEMIA: NHP MODEL MALARIAL ANEMIA
红细胞感染和贫血的机制:NHP 模型疟疾贫血
- 批准号:
8172365 - 财政年份:2010
- 资助金额:
$ 41.81万 - 项目类别:
Tubovesicular traffic induced in red cells in plasmodia
疟原虫红细胞中诱导的管泡交通
- 批准号:
8054523 - 财政年份:2010
- 资助金额:
$ 41.81万 - 项目类别:
MECHANISMS OF ERYTHROCYTIC INFECTIONS AND ANEMIA: NHP MODEL MALARIAL ANEMIA
红细胞感染和贫血的机制:NHP 模型疟疾贫血
- 批准号:
7958179 - 财政年份:2009
- 资助金额:
$ 41.81万 - 项目类别:
MECHANISMS OF ERYTHROCYTIC INFECTIONS AND ANEMIA: NHP MODEL MALARIAL ANEMIA
红细胞感染和贫血的机制:NHP 模型疟疾贫血
- 批准号:
7715763 - 财政年份:2008
- 资助金额:
$ 41.81万 - 项目类别:
MECHANISMS OF ERYTHROCYTIC INFECTIONS AND ANEMIA: NHP MODEL MALARIAL ANEMIA
红细胞感染和贫血的机制:NHP 模型疟疾贫血
- 批准号:
7562623 - 财政年份:2007
- 资助金额:
$ 41.81万 - 项目类别:
MECHANISMS OF ERYTHROCYTIC INFECTIONS AND ANEMIA: NHP MODEL MALARIAL ANEMIA
红细胞感染和贫血的机制:NHP 模型疟疾贫血
- 批准号:
7349291 - 财政年份:2006
- 资助金额:
$ 41.81万 - 项目类别:
Erythrocyte Raft Signaling In Malarial Infection
疟疾感染中的红细胞筏信号传导
- 批准号:
7173331 - 财政年份:2005
- 资助金额:
$ 41.81万 - 项目类别:
Mechanisms of Erythrocytic Infection & Anemia in Malaria
红细胞感染的机制
- 批准号:
7282022 - 财政年份:2005
- 资助金额:
$ 41.81万 - 项目类别:
相似海外基金
Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
- 批准号:
MR/X030202/1 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
- 批准号:
10742205 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
- 批准号:
10635649 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10534667 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10533634 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别:
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
- 批准号:
468862 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别:
Operating Grants
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
- 批准号:
2749037 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别:
Studentship
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10646331 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10368441 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10663334 - 财政年份:2022
- 资助金额:
$ 41.81万 - 项目类别: